Zhongshan Laibo Ruichen Biomedicine Co., Ltd.(Rabpharma), founded in 2021, is a biopharmaceutical company  focused on the research, development, and commercialization of innovative therapeutics for bone and joint diseases.

Our R&D team is led by Prof. Wei Yao, a renowned expert in bone and joint regenerative medicine from UC Davis. The core members consist of scientists and researchers with backgrounds from world-class institutions and extensive experience at leading pharmaceutical companies including Merck, Bayer, and WuXi AppTec, etc. 

Rabpharma specializes in developing first-in-class therapeutics for skeletal disorders. Our first innovative drug,  RAB001, targeting to the treatment of osteonecrosis, has completed Phase I trials both in the U.S. and China. Since December 2024, a Phase II clinical trial has been initiated in 25 hospitals all around China. We are also advancing a pipeline of innovative preclinical assets targeting a wider spectrum of bone and joint disorders.

And since establishment, Rabpharma has successfully closed three funding rounds,  accelerating clinical development and pipeline expansion.  

We are committed to our mission: to provide patients with more and better treatment options for bone and joint disorders.